Lori A. Woods
About Lori A. Woods
Lori A. Woods (age 62) serves as Chairperson of the Board at Perspective Therapeutics (CATX); she has been a director since June 4, 2018 and previously served as CEO from December 2018 to February 2023, bringing two decades of life sciences commercialization and brachytherapy operations experience and a B.S. in Business Administration (Marketing & Communications) from Loma Linda University . She is currently classified as not independent under NYSE American standards due to her employment within the last three years .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Perspective Therapeutics (CATX) | Chairperson of the Board; Director | Chair since Feb 3, 2023; Director since Jun 4, 2018 | Board leadership; separated CEO/Chair enhances oversight |
| Perspective Therapeutics (CATX) | Chief Executive Officer | Dec 2018 – Feb 2023 | Led transition through Viewpoint merger era; CEO tenure noted in pay-versus-performance disclosures |
| Perspective Therapeutics (CATX) | VP; Acting COO; COO; Senior Consultant; Interim CEO | VP 2006–Feb 2008; Acting COO Feb 2008; COO Feb 2009–Jan 2010; Senior Consultant Feb 2016–Jun 2018; Interim CEO Jun 4, 2018 | Operations leadership and commercialization support |
| Pro-Qura, Inc. (private) | Chief Executive Officer | Jan 2002 – Jul 2006 | Brachytherapy quality delivery program management |
| Tumor Institute Radiation Oncology Group; Seattle Prostate Institute | Director of Business Development | Prior to 2002 (dates not specified) | SPI trained 2,000+ physicians in prostate brachytherapy |
| Medvio, LLC (private) | Founder/Consultant (urology/oncology devices) | Feb 2016 – Jun 2018 | Regulatory approvals, international distribution; tech development for colorectal/liver markets |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Juvenile Diabetes Research Foundation (Northwest) | Board member (non-profit) | Not specified | Focused on digital awareness/SEO and public relations |
Board Governance
- Board composition: five members; Woods is Chair; other independent directors are H. Henson, F. Morich, and R. F. Williamson; CEO J. Spoor is not independent .
- Committee structure and current membership: Audit (Henson—Chair; Williamson; Morich), Compensation (Williamson—Chair; Henson; Morich), and Nominations (Morich—Chair; Williamson; Henson); Woods not currently serving on committees .
- Prior committee service: Woods previously served as a non‑independent member of the Compensation and Nominations Committees during 2024 and early 2025 under NYSE American Sections 805(b) and 804(b) exceptions .
- Meetings/attendance: Board held seven meetings; each director attended at least 75% of Board and committee meetings during 2024; committees met Audit (4), Compensation (7), Nominations (2) .
- Board leadership: roles of Chair and CEO are separated, with stated oversight benefits (objective CEO evaluation, risk oversight, investor communications); independent directors meet at least annually in executive session .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual director cash retainer | $60,000 | Non-employee directors |
| Chair of the Board additional retainer | $30,000 | Applies to Woods |
| Committee chair fees | $15,000 per committee chair | Not applicable to Woods in 2024 |
| Meeting fees | None disclosed | — |
| 2024 fees earned by Woods | $90,000 | Cash total for 2024 |
- Cash/equity mix for 2024: $90,000 cash and $192,540 option award fair value (approx. 31.8% cash / 68.2% equity) .
Performance Compensation
| Equity Award | Grant Size | Vesting | Term | Fair Value (2024) |
|---|---|---|---|---|
| Annual director stock options (2024 policy) | 23,000 options per non-employee director | 100% vests on first anniversary of grant date | 10 years | $192,540 (Woods) |
- Equity grant practices: grants approved in/after Q1 meetings; grant date price at closing stock price; no timing to exploit MNPI; 2024 awards not granted within blackout-adjacent windows; no option repricings in 2023–2024 .
Other Directorships & Interlocks
| Company | Role | Public Company? | Potential Interlocks/Conflicts |
|---|---|---|---|
| None disclosed | — | — | No public company directorships disclosed for Woods |
- Independent committee composition and financial expert designation reside with other directors (e.g., Henson as Audit Committee financial expert) .
- Related party context: Lantheus Alpha owns ~15.77% and entered investment, option, asset purchase, and access/license agreements with CATX; oversight via Audit Committee; no specific Woods-related transaction disclosed .
Expertise & Qualifications
- Life sciences commercialization and brachytherapy quality management; executive leadership (CEO/COO); international device approvals and distribution; oncology/urology markets .
- Education: B.S. in Business Administration (Marketing & Communications), Loma Linda University .
Equity Ownership
| Holder | Common Shares | Options (exercisable ≤60 days) | % of Class | Notes |
|---|---|---|---|---|
| Lori A. Woods | 188,267 | 229,505 | <1% | 4,807 held directly; 183,460 held in a trust |
| Director options outstanding (as of 12/31/2024) | — | — | — | Woods aggregate options outstanding: 264,250 |
- Insider trading policy prohibits short sales, derivative hedging, and pledging/margin accounts for directors and employees; no pledging disclosed for Woods .
Governance Assessment
-
Strengths:
- Separated Chair/CEO roles and independent committee leadership enhance oversight and risk management .
- Audit Committee financial expert and strong independence across key committees .
- Clear insider trading, hedging, and pledging prohibitions; clawback policy for executives .
- Documented director attendance at or above 75% and full Board presence at the annual meeting .
-
Concerns/RED FLAGS:
- Chair not independent due to recent prior CEO service; potential for perceived influence over compensation and nominations despite committee independence .
- Prior non‑independent service by Woods on Compensation and Nominations committees in 2024/early 2025 (permitted by NYSE American exceptions), which can be viewed as a governance risk if extended .
- Significant related-party commercial and investment arrangements with a >10% holder (Lantheus); while overseen by Audit Committee, heightened conflict vigilance is warranted .
-
Alignment:
- Director pay is majority equity via annual option grants with 1-year cliff vesting, promoting stock-price alignment; Woods holds both common shares and vested options, albeit <1% ownership of outstanding shares .
-
Engagement:
- Attendance thresholds met; independent directors meet in executive session at least annually .
Implications: Investors should monitor the Board’s continued adherence to independent committee control, the sunset of non‑independent committee participation, and the oversight of Lantheus-related transactions to mitigate perceived conflicts while maintaining strategic optionality in radiopharmaceutical partnerships .